References
- Mazzucco W, Cusimano R, Mazzola S. Childhood and adolescence cancers in the Palermo Province (Southern Italy): Ten years (2003–2012) of epidemiological surveillance. Int J Environ Res Public Health. 2018;15(7):1344.
- Cancer Network organization K. Kenya cancer statistics & national strategies [Internet]. 2016. [cited 2018 Jun 14]. Available from: https://kenyacancernetwork.wordpress.com/.
- Mutuma G, Korir A. The burden of childhood cancers in nairobi, kenya (2000–2006) – pattern, trends, risk factors and epidemiology. Afr J Health Sci. 2011;19:34.
- Philips S, Padgett L, Leisenring W, et al. Survivors of childhood cancer in the United States: prevalence and burden of morbidity. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. Am Soc Prev Oncol. 2015;24(4):653–663.
- Lymphoma society L and Non-Hodgkin Lymphoma. 2013. 56 p. [cited 2018 Feb 14]. Available from: https://www.lls.org/sites/default/files/file_assets/nhl.pdf
- Budiongo A, Ngiyulu R, Lebwaze B, et al. Pediatric non-Hodgkin lymphomas: first report from Central Africa. Pediatr Hematol Oncol. 2015;32(4):239–249.
- Gross TT, Andrea B. Paediatric non-Hodgkin lymphoma in low and middle income countries. Br J Haematol. 2016;173(4):651–654.
- AKa P, Kawira E, Masalu N, et al. Incidence and trends in Burkitt lymphoma in northern Tanzaniz from 2000 to 2009. Pediatr Blood Cancer. 2012;59(7):1234–1238.
- Omondi M, Opanga S, Martin A, et al. Pilot study assessing the direct medical cost of treating patients with cancer in Kenya; findings and implications for the future. J Med Econ. 2018;21(9):878–887.
- Epeldegui M, Vendrame E, Martínez-Maza O. HIV-associated immune dysfunction and viral infection: role in the pathogenesis of AIDS-related lymphoma. J Immunol Res. 2010;48:72–83.
- UNDP. UNDP on Botswana HIV [Internet]. [ cited 2018 Jan 10]. Available from: http://www.bw.undp.org/content/botswana/en/home/ourwork/hiv_aids/overview.html.
- Wang H, Wolock T, Nguyen G, et al. Estimates of global,regional and national incidence,prevalence and mortality of HIV,1980–2015: the global burden of disease study 2015. Lancet HIV. 2016;3(8):361–387.
- Ngambi P, Kalungia A, Law M, et al. Evidence on the cost-effectiveness of lifelong antiretroviral therapy for prevention of mother to child transmission of HIV:implications for resource-limited countries in sub-saharan Africa. Expert Rev Pharmacoeconomics Outcomes Res. 2017;17(5):459–467.
- National AIDS Control Council. Kenya HIV estimates- Report 2018. [cited 2019 Apr 1]. Available at:https://nacc.or.ke/wp-content/uploads/2018/12/HIV-estimates-report-Kenya-20182.pdf.
- Canadian Cancer Society. 2019, Risk factors for non-Hodgkin lymphoma. [cited 2019 Apr 1]. Available from: http://www.cancer.ca/en/cancer-information/cancer-type/non-hodgkin-lymphoma/risks/?region=on.
- Mbulaiteye S, Bhatia K, Biggar R, et al. Sporadic Burkitt lymphoma incidence in the United states during 1992–2005. Pediatr Blood Cancer. 2009;53(3):366–370.
- Huang H, Hsiao F, Chen L, et al. Women with diffuse large B cell lymphoma benefit from rituximab-containing chemotherapy. J Womenens Health. 2018 Jun 20. [cited 2018 Jul 20]. Available from: https://visualizinghealthdata.idv.tw/?route=article/thesis&id=29924676
- Griffin M, Morley N. Rituximab in the treatment of non-Hodgkin’s lymphoma–a critical evaluation of randomized controlled trials. Expert Opin Biol Ther. 2013;13(5):803–811.
- American Cancer Society. Chemotherapy for non-Hodgkin lymphoma. [cited 2018 Jun 14]. Available from: https://www.cancer.org/cancer/non-hodgkin-lymphoma/treating/chemotherapy.html.
- Zeltzer P, LeBaron S, Zeltzer L. Chemotherapy side effects in pediatric oncology patients: drugs, age, and sex as risk factors. Med Paediatr Oncol. 1988;16(4):263–268.
- Fleishman BS Understanding and managing chemotherapy side effects. Cancer care. 2018. [cited 2018 Jul 25]. Available from: https://media.cancercare.org/publications/original/24-ccc_chemo_side_effects.pdf.
- Hamilton S low blood counts-managing side effects [Internet]. Chemocare. 2002. [cited 2018 Jun 14]. Available from: http://chemocare.com/chemotherapy/side-effects/low-blood-counts.
- WHO. WHO guidelines on pharmacological treatment of persisting pain in children with medical illnesses. 2012 p. 84. [cited 2018 Oct 5]. Available from: http://apps.who.int/iris/bitstream/handle/10665/44540/9789241548120_Guidelines.pdf;jsessionid=825223873BCC30B417A8D3887219D506?sequence=1.
- Gotti M, Fiaccadori V, Bono E, et al. Therapy-related late adverse events in Hodgkin’s lymphoma. Lymphoma. 2013;2013:1–7.
- Cochran GW Sampling techniques [Internet]. third ed. John Willey and Sons; 1977. [cited 2018 Jul 20]. Available from: https://hwbdocuments.env.nm.gov/Los%20Alamos%20National%20Labs/General/14447.pdf.
- American Cancer Society. No titlechemotherapy for non Hodking lymphoma. [cited 2017 Jun 29]. Available from: https://www.cancer.org/cancer/non-hodgkin-lymphoma/treating/chemotherapy.html.
- American Cancer Society. About non-Hodgkin lymphoma in children what are the differences between cancers in adults and children? 2016. [cited 2017 Jun 29]. Available from: https://www.cancer.org/content/dam/CRC/PDF/Public/8723.00.pdf.
- National Cancer Institute. Childhood non-Hodgkin lymphoma treatment (PDQ®): health professional version. PDQ cancer information summaries. 2017. [cited 2017 Jun 29]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/26389181.
- Office of the Director of Medical Services. National guidelines for cancer management Kenya; 2013 August; Ministry of Health, Nairobi: p. 22.
- Dorak MT, Ebru K. Gender differences in cancer susceptibility: an inadequately addressed issue. Front Genet. 2012;3:1–11.
- Muller AM, Ihorst G, Mertelsmann R, et al. Epidemiology of non-Hodgkin’s lymphoma (NHL): trends, geographic distribution, and etiology. Ann Hematol. 2005;84(1):1–12.
- Masakhwe C, Ochanda H, Nyakoe N, et al. Frequency of Epstein - Barr Virus in patients presenting with acute febrile illness in Kenya. PLoS ONE. 2016;11(5):1–14.
- Scholten W WHO persisting pediatric pain guidelines: a research agenda [Internet]. Powerpoint presented at: third partners meeting on better medicines for children; 2011; Geneva (Switzerland). [cited 2018 Jun 14]. Available from: http://www.who.int/childmedicines/partners/ScholtenW_Partners.pdf.
- Atieno OM, Opanga S, Martin A, et al. Pilot study assessing the direct medical cost of treating patients with cancer in Kenya; findings and implications for the future. J Med Econ. 2018;21(9):878–887.
- Ludwig H, Gascón P, Bokemeyer C, et al. Outcomes of chemotherapy-induced (febrile) neutropenia prophylaxis with biosimilar filgrastim (Zarzio®) initiated “same-day”(< 24 h),“per-guidelines”(24–72 h), and “late”(> 72 h): findings from the MONITOR-GCSF study. Support Care Cancer. 2018; doi:10.1007/s00520-018-4513-6.
- Geeta MG, Ajithkumar VT, Krishnakumar PML, et al. management of pain in leukemic children using WHO analgesic ladder. Indian J Pediatr. 2010;77:665.
- Mbui J, Oluka M, Guantai E, et al. Prescription patterns and adequacy of blood pressure control among adult hypertensive patients in Kenya; Findings and implications. Expert Rev Clin Pharmacol. 2017;10(11):1263–1271.